Osimertinib – a new oral third‑generation EGFR TKI

02/2017

MUDr. Leona Koubková

Pneumologická klinika 2. LF UK a FN v Motole, Praha

SUMMARY

Non-small cell lung cancer (NSCLC) is a disease with a poor prognosis. Today we know that it involves a genetically distinct group of tumors. And of such genetic diversity leads to the tendency of individualized treatments based on the predictive factors that predict the efficacy of treatment. One of the predictive factors in NSCLC are mutations of the epidermal growth factor receptor (EGFR), in which case is indicated treatment EGFR tyrosine kinase inhibitors (TKI). Even if this treatment, we have to calculate with the formation of resistance. The mechanisms of its formation are different, most (up 60%), it is the T790M mutation at exon 20. In 11/2015 FDA and 2/2016 EMA approved EGFR TKI 3^rd generation osimertinib to treat patients with locally advanced or metastatic NSCLC T790M mutation of EGFR.

KEY WORDS

non-small cell lung cancer, mutation of EGFR, EGFR tyrosine kinase inhibitors, osimertinib, resistance